APOC1 T45S polymorphism is associated with reduced obesity indices and lower plasma concentrations of leptin and apolipoprotein C-I in aboriginal Canadians

Journal of Lipid Research

Volumn 51, Issue 4, 2010, Pages 843-848

  Lahiry, Piya ^a   Cao, Henian ^a   Ban, Matthew R ^a   Pollex, Rebecca L ^a   Mamakeesick, Mary ^b   Zinman, Bernard ^b   Harris, Stewart B ^c   Hanley, Anthony J G ^d   Huff, Murray W ^a   Connelly, Philip W ^e   Hegele, Robert A ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b Sandy Lake Health and Diabetes Project   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Canadian First Nation population; Genetics; Hypertriglyceridemic waist; Leptin; Nonsynonymous variant; Serum levels

Indexed keywords

AMINO ACID; APOLIPOPROTEIN C1; LEPTIN; LIPOPROTEIN; SERINE; THREONINE; APOLIPOPROTEIN C-I, HUMAN;

ABORIGINE; ADULT; ARTICLE; BODY FAT; CANADA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN METABOLISM; WAIST CIRCUMFERENCE; ADOLESCENT; AMERICAN INDIAN; BLOOD; BODY COMPOSITION; CHILD; GENETIC ASSOCIATION; GENETICS; HYPERTRIGLYCERIDEMIA; OBESITY, ABDOMINAL; PREVALENCE; SEXUAL DEVELOPMENT; YOUNG ADULT;

ADOLESCENT; ADULT; APOLIPOPROTEIN C-I; BODY COMPOSITION; CANADA; CHILD; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HUMANS; HYPERTRIGLYCERIDEMIA; INDIANS, NORTH AMERICAN; LEPTIN; MALE; OBESITY; OBESITY, ABDOMINAL; POLYMORPHISM, GENETIC; PREVALENCE; SEX CHARACTERISTICS; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 77950607705     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P002014     Document Type: Article

References (48)

1. Pollex, R. L., A. J. Hanley, B. Zinman, S. B. Harris, and R. A. Hegele. 2006. Clinical and genetic associations with hypertriglyc-eridemic waist in a Canadian aboriginal population. Int. J. Obes. 30: 484-491.
2. Pollex, R. L., M. Mamakeesick, B. Zinman, S. B. Harris, R. A. Hegele, and A. J. Hanley. 2007. Peroxisome proliferator-activated receptor gamma polymorphism Pro12Ala is associated with ne-phropathy in type 2 diabetes. J. Diabetes Complications. 21: 166-171.
3. Jong, M. C., M. H. Hofker, and L. M. Havekes. 1999. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler. Thromb. Vasc. Biol. 19: 472-484.
4. Soutar, A. K., C. W. Garner, H. N. Baker, J. T. Sparrow, R. L. Jackson, A. M. Gotto, and L. C. Smith. 1975. Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin: cholesterol acyltransferase. Biochemistry. 14: 3057-3064.
5. Conde-Knape, K., A. Bensadoun, J. H. Sobel, J. S. Cohn, and N. S. Shachter. 2002. Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase. J. Lipid Res. 43: 2136-2145.
6. Kinnunen, P. K., and C. Ehnolm. 1976. Effect of serum and C-apoproteins from very low density lipoproteins on human pos-theparin plasma hepatic lipase. FEBS Lett. 65: 354-357.
7. Gautier, T., D. Masson, J. P. de Barros, A. Athias, P. Gambert, D. Aunis, M. H. Metz-Boutigue, and L. Lagrost. 2000. Human apolipo-protein C-I accounts for the ability of plasma high density lipopro-teins to inhibit the cholesteryl ester transfer protein activity. J. Biol. Chem. 275: 37504-37509.
8. Berbee, J. F., C. C. van der Hoogt, D. Sundararaman, L. M. Havekes, and P. C. Rensen. 2005. Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. J. Lipid Res. 46: 297-306.
9. Westerterp, M., M. Van Eck, W. de Haan, E. H. Offerman, T. J. Van Berkel, L. M. Havekes, and P. C. Rensen. 2007. Apolipoprotein CI aggravates atherosclerosis development in ApoE-knockout mice despite mediating cholesterol effl ux from macrophages. Atherosclerosis. 195: e9-e16.
10. Sehayek, E., and S. Eisenberg. 1991. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J. Biol. Chem. 266: 18259-18267.
11. Weisgraber, K. H., R. W. Mahley, R. C. Kowal, J. Herz, J. L. Goldstein, and M. S. Brown. 1990. Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein. J. Biol. Chem. 265: 22453-22459.
12. Jong, M. C., V. E. Dahlmans, P. J. van Gorp, K. W. van Dijk, M. L. Breuer, M. H. Hofker, and L. M. Havekes. 1996. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway. J. Clin. Invest. 98: 2259-2267.
13. Westerterp, M., W. de Haan, J. F. Berbee, L. M. Havekes, and P. C. Rensen. 2006. Endogenous apoC-I increases hyperlipidemia in apoE-knockout mice by stimulating VLDL production and inhibiting LPL. J. Lipid Res. 47: 1203-1211.
14. Lusis, A. J., A. M. Fogelman, and G. C. Fonarow. 2004. Genetic ba-sis of atherosclerosis: part II: clinical implications. Circulation. 110: 2066-2071.
15. Hegele, R. A. 2009. Plasma lipoproteins: genetic infl uences and clinical implications. Nat. Rev. Genet. 10: 109-121.
16. Frossard, P. M., R. T. Coleman, M. J. Malloy, J. P. Kane, B. Levy-Wilson, and V. A. Appleby. 1987. Human apolipoprotein CI (apoC1) gene locus: DraI dimorphic site. Nucleic Acids Res. 15: 1884.
17. Frossard, P. M., D. W. Lim, R. T. Coleman, H. Funke, G. Assmann, M. J. Malloy, and J. P. Kane. 1987. Human apolipoprotein CI (ApoC1) gene locus: BglI dimorphic site. Nucleic Acids Res. 15: 1344.
18. Smit, M., E. van der Kooij-Meijs, L. P. Woudt, L. M. Havekes, and R. R. Frants. 1988. Exact localization of the familial dysbetalipopro-teinemia associated HpaI restriction site in the promoter region of the APOC1 gene. Biochem. Biophys. Res. Commun. 152: 1282-1288.
19. Hubacek, J. A., D. M. Waterworth, R. Poledne, J. Pitha, Z. Skodova, S. E. Humphries, and P. J. Talmud. 2001. Genetic determination of plasma lipids and insulin in the Czech population. Clin. Biochem. 34: 113-118.
20. Shachter, N. S., D. Rabinowitz, S. Stohl, K. Conde-Knape, J. S. Cohn, R. J. Deckelbaum, L. Berglund, and S. Shea. 2005. The common insertional polymorphism in the APOC1 promoter is associated with serum apolipoprotein C-I levels in Hispanic children. Atherosclerosis. 179: 387-393.
21. Abildayeva, K., J. F. Berbee, A. Blokland, P. J. Jansen, F. J. Hoek, O. Meijer, D. Lutjohann, T. Gautier, T. Pillot, J. De Vente, et al. 2008. Human apolipoprotein C-I expression in mice impairs learning and memory functions. J. Lipid Res. 49: 856-869.
22. Li, H., S. Wetten, L. Li, P. L. St Jean, R. Upmanyu, L. Surh, D. Hosford, M. R. Barnes, J. D. Briley, M. Borrie, et al. 2008. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch. Neurol. 65: 45-53.
23. Tycko, B., J. H. Lee, A. Ciappa, A. Saxena, C. M. Li, L. Feng, A. Arriaga, Y. Stern, R. Lantigua, N. Shachter, et al. 2004. APOE and APOC1 promoter polymorphisms and the risk of Alzheimer disease in African American and Caribbean Hispanic individuals. Arch. Neurol. 61: 1434-1439.
24. Shi, J., S. Zhang, C. Ma, X. Liu, T. Li, M. Tang, H. Han, Y. Guo, J. Zhao, K. Zheng, et al. 2004. Association between apolipoprotein CI HpaI polymorphism and sporadic Alzheimer's disease in Chinese. Acta Neurol. Scand. 109: 140-145. (Pubitemid 38175054)
25. Kasthuri, R. S., K. R. McMillan, C. Flood-Urdangarin, S. B. Harvey, J. T. Wilson-Grady, and G. L. Nelsestuen. 2007. Correlation of a T45S variant of apolipoprotein C1 with elevated BMI in persons of American Indian and Mexican ancestries. Int. J. Obes. 31: 1334-1336.
26. Hanley, A. J. G., S. B. Harris, A. Barnie, J. Gittelsohn, T. M. S. Wolever, A. Logan, and B. Zinman. 1995. The Sandy Lake Health and Diabetes Project: design, methods and lessons learned. Chronic Dis. Can. 16: 149-156.
27. Gittelsohn, J., T. M. Wolever, S. B. Harris, R. Harris-Giraldo, A. J. Hanley, and B. Zinman. 1998. Specifi c patterns of food consumption and preparation are associated with diabetes and obesity in a Native Canadian community. J. Nutr. 128: 541-547.
28. Harris, S. B., B. Zinman, A. Hanley, J. Gittelsohn, R. Hegele, P. W. Connelly, B. Shah, and J. E. Hux. 2002. The impact of diabetes on cardiovascular risk factors and outcomes in a native Canadian population. Diabetes Res. Clin. Pract. 55: 165-173.
29. Kriska, A. M., A. J. Hanley, S. B. Harris, and B. Zinman. 2001. Physical activity, physical fi tness, and insulin and glucose concentrations in an isolated Native Canadian population experiencing rapid lifestyle change. Diabetes Care. 24: 1787-1792.
30. Hegele, R. A., A. J. Evans, L. Tu, G. Ip, J. H. Brunt, and P. W. Connelly. 1994. A gene-gender interaction affecting plasma lipo-proteins in a genetic isolate. Arterioscler. Thromb. 14: 671-678.
31. Hegele, R. A., S. B. Harris, A. J. Hanley, F. Sun, P. W. Connelly, and B. Zinman. 1997. Angiotensinogen gene variation associated with variation in blood pressure in aboriginal Canadians. Hypertension. 29: 1073-1077. (Pubitemid 27198326)
32. Lemieux, I., A. Pascot, C. Couillard, B. Lamarche, A. Tchernof, N. Almeras, J. Bergeron, D. Gaudet, G. Tremblay, D. Prud'homme, et al. 2000. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation. 102: 179-184
33. Executive Summary of The Third Report of The National Cho-lesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). 2001. J. Am. Med. Assoc. 285: 2486-2497.
34. Bury, J., G. Michiels, and M. Rosseneu. 1986. Human apolipopro-tein C-II quantitation by sandwich enzyme-linked immunosorbent assay. J. Clin. Chem. Clin. Biochem. 24: 457-463.
35. Lauer, S. J., D. Walker, N. A. Elshourbagy, C. A. Reardon, B. Levy-Wilson, and J. M. Taylor. 1988. Two copies of the human apolipo-protein C-I gene are linked closely to the apolipoprotein E gene. J. Biol. Chem. 263: 7277-7286.
36. Simonet, W. S., N. Bucay, S. J. Lauer, and J. M. Taylor. 1993. A far-downstream hepatocyte-specifi c control region directs expression of the linked human apolipoprotein E and C-I genes in transgenic mice. J. Biol. Chem. 268: 8221-8229.
37. Shulman, R. S., P. N. Herbert, K. Wehrly, and D. S. Fredrickson. 1975. The complete amino acid sequence of C-I (apoLp-Ser), an apolipoprotein from human very low density lipoproteins. J. Biol. Chem. 250: 182-190.
38. Rozek, A., G. W. Buchko, and R. J. Cushley. 1995. Conformation of two peptides corresponding to human apolipoprotein C-I residues 7-24 and 35-53 in the presence of sodium dodecyl sulfate by CD and NMR spectroscopy. Biochemistry. 34: 7401-7408.
39. Dumon, M. F., and M. Clerc. 1986. Preliminary report on a case of apolipoproteins CI and CII defi ciency. Clin. Chim. Acta. 157: 239-248.
40. Lin, P. I., J. M. Vance, M. A. Pericak-Vance, and E. R. Martin. 2007. No gene is an island: the fl ip-fl op phenomenon. Am. J. Hum. Genet. 80: 531-538.
41. Kowal, R. C., J. Herz, K. H. Weisgraber, R. W. Mahley, M. S. Brown, and J. L. Goldstein. 1990. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J. Biol. Chem. 265: 10771-10779.
42. Jong, M. C., M. J. Gijbels, V. E. Dahlmans, P. J. Gorp, S. J. Koopman, M. Ponec, M. H. Hofker, and L. M. Havekes. 1998. Hyperlipidemia and cutaneous abnormalities in transgenic mice overexpressing human apolipoprotein C1. J. Clin. Invest. 101: 145-152.
43. Shachter, N. S., T. Ebara, R. Ramakrishnan, G. Steiner, J. L. Breslow, H. N. Ginsberg, and J. D. Smith. 1996. Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl. J. Clin. Invest. 98: 846-855.
44. Jong, M. C., J. H. van Ree, V. E. Dahlmans, R. R. Frants, M. H. Hofker, and L. M. Havekes. 1997. Reduced very-low-density lipo-protein fractional catabolic rate in apolipoprotein C1-defi cient mice. Biochem. J. 321: 445-450.
45. de Haan, W., R. Out, J. F. Berbee, C. C. van der Hoogt, K. W. van Dijk, T. J. van Berkel, J. A. Romijn, J. W. Jukema, L. M. Havekes, and P. C. Rensen. 2008. Apolipoprotein CI inhibits scavenger receptor BI and increases plasma HDL levels in vivo. Biochem. Biophys. Res. Commun. 377: 1294-1298.
46. Zhao, Y., F. E. Thorngate, K. H. Weisgraber, D. L. Williams, and J. S. Parks. 2005. Apolipoprotein E is the major physiological activator of lecithin-cholesterol acyltransferase (LCAT) on apolipoprotein B lipoproteins. Biochemistry. 44: 1013-1025.
47. Wroblewski, M. S., J. T. Wilson-Grady, M. B. Martinez, R. S. Kasthuri, K. R. McMillan, C. Flood-Urdangarin, and G. L. Nelsestuen. 2006. A functional polymorphism of apolipoprotein C1 detected by mass spectrometry. FEBS J. 273: 4707-4715.
48. van der Ham, R. L., R. Alizadeh Dehnavi, J. F. Berbee, H. Putter, A. de Roos, J. A. Romijn, P. C. Rensen, and J. T. Tamsma. 2009. Plasma apolipoprotein CI and CIII levels are associated with increased plasma triglyceride levels and decreased fat mass in men with the metabolic syndrome. Diabetes Care. 32: 184-186.